Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities t ...

QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results [Accessibility Statement] Skip Navigation Delivered 6% Labs and 9% TRIAGEâ"¢ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today an ...

NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of an aggregate of 4,525,976 shares of its common stock, no par value per share (or pre-funded warrants in lieu thereof) at an offering price of $5.75 per share in a registered direct offering. The purchase price per pre-funded warrant is identical to the ...

Core Viewpoint - Quest Diagnostics has received a stock upgrade to "Buy" from Jefferies, reflecting confidence in its financial health and growth prospects, with a price target increase from $215 to $220 [1][6] Financial Performance - In Q4 2025, Quest Diagnostics reported revenues of $2.81 billion, a 7.1% increase from the previous year, with diluted EPS rising by 11.8% to $2.18 and adjusted EPS at $2.42 [2] - For the full year 2025, the company achieved revenues of $11.04 billion, an 11.8% increase from 2024, with diluted EPS at $8.75 (up 13.8%) and adjusted EPS at $9.85 (up 10.3%) [3] Future Projections - Quest Diagnostics projects 2026 revenues between $11.70 billion and $11.82 billion, with expected diluted EPS between $9.45 and $9.65, and adjusted EPS ranging from $10.50 to $10.70, supported by strategic focus on clinical innovations [4] Shareholder Returns - The company announced a 7.5% increase in its quarterly dividend to $0.86 per share, marking the 15th consecutive year of dividend increases, and authorized a $1 billion increase in its share repurchase program [5][6]

The countdown is on. Everything you need to get the edge at the end of the market day. Live from Studio two at Bloomberg headquarters in New York, I'm Katie Greenfield and standing next to me.Hello, Scarlet Fu. Hello. It's an it it's not even an ETF like you did, not even a monday.All right. We're kicking you off to the closing bell here in the US on this Tuesday with stocks mixed Right now, you do have the S&P 500 lower by a 10th of 1%, but we're still pretty much near record highs in terms of the gainers ...

BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) â"¢ MENLO PARK, Calif., Feb. 9, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of UNITY's expanded Red Blood Cell (RBC) Fetal Antigen NIPT and a first-and- only Plate ...

SALT LAKE CITY, Feb. 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in an exhibition at the upcoming World Health Expo Labs Dubai ("WHX Labs"), taking place February 10–13, 2026, at the Dubai World Trade Centre. World Health Expo Labs Dubai, formerly Medlab Middle East, is a multi-day international exhibition that c ...

Key Takeaways DGX is set to report Q4 results on Feb. 10, with sales and EPS expected to grow 4.8% and 5.4%, respectively.DGX's DIS business is expected to post strong Q4 growth, aided by physician demand and Fresenius assets. Quest Diagnostics sees Advanced Diagnostics and consumer testing lift Q4, with non-GAAP income up 11.6%. Quest Diagnostics (DGX) is set to release fourth-quarter 2025 results on Feb. 10, before the market opens.The renowned diagnostics provider posted adjusted earnings per share (EPS) ...

FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA li ...

ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring. Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with developing ...